Name: | Description: | Size: | Format: | |
---|---|---|---|---|
351.64 KB | Adobe PDF |
Advisor(s)
Abstract(s)
ASAS and EULAR recommend the use of an improvement ≥1.1 in ASDAS at 12 weeks to determine the continuation of a bDMARD.
However, it is debated whether improvements can occur and whether patients’ characteristics influence (time to) response.
Description
Keywords
Citation
Publisher
Clinical and Experimental Rheumatology